Novartis held the line on spend in '09

Novartis' US sales reorganization seems to have paid off in 2009 as the company held the line on sales and marketing expenses despite a passel of global launches.

The company said in its 2009 results that sales and marketing spend for its pharmaceutical division fell 1.6 percentage points to 29.3% of net sales in 2009 thanks to productivity improvements—even as it launched a host of new products, including Galvus, Exelon Patch, Valturna and the Tekturna/Rasilez franchise.

Novartis announced a realignment of its US commercial model, dubbed its “Customer Centric Initiative,” in October 2008. The reorganization replaced Novartis' managed sales force with five regional units tasked with cross-functional responsibility for primary care. Novartis shed 550 sales spots, most through attrition.

Elsewhere, while noting strong productivity gains in sales and marketing at its Sandoz unit, Novartis said core operating income for its consumer health division fell 1% to $1.1 billion due to heavy outlays for the launch of OTC Prevacid24HR in the US.

Overall, net sales were up 7% in US dollars and 11% in local currencies to $44.2 billion for the full year. Fourth-quarter sales rose a whopping 28% in US dollars (20% in local currencies) compared to the same period in 2008, to $12.9 billion.

Earlier in the year, MM&M named Novartis its Company of the Year.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.